This Pill Tricks Your Body Into Fasting (It Works) : 1574
Nov 15, 2026 · 15m
More Science podcasts · More Self-Improvement podcasts
Summary
Dave Asprey explores SGLT2 inhibitors, FDA-approved diabetes drugs that induce a fasting-like metabolic state by blocking glucose reabsorption in the kidneys. He discusses recent evidence showing these "caloric restriction mimetics" activate longevity pathways, clear senescent cells, and even lengthen telomeres. The episode covers how to access these prescriptions off-label for health optimization, while highlighting risks like dehydration and euglycemic ketoacidosis.
Topics discussed
Sponsor: Echo Flask hydrogen water benefits
Sponsor: Vital C ESS60 for cellular energy
Introduction: The history of the 'fasting pill'
Fluorizin: From poison to diabetes mystery
Kidney mechanics and the SGLT2 protein target
Caloric loss via urine and weight loss reality
Cardiovascular benefits and the EMPA-REG trial
Inducing ketosis and fasting pathways (AMPK, SIRT1)
Caloric restriction mimetics and the 2024 trial
Trial results: Telomere length and blood chemistry
Immune function and IGF-1 biomarkers
Accessing SGLT2 inhibitors in the US
Longevity clinic use and senolytic effects
Sponsor: Kinetic ketones for brain focus
Sponsor: Essentia mattress for sleep quality
Lifespan extension and anti-aging drug rankings
Risks: Infections, dehydration, and ketoacidosis
Future of biohacking and fasting challenges
Podcast credits and medical disclaimers
More from The Human Upgrade: Biohacking for Longevity & Performance
Listen ad-free on Castria